Frontier Medicines Corporation today announced upcoming presentations featuring preclinical data on its novel dual KRASG12C inhibitor FMC-376 and advances from the Frontier™ Platform.
BOSTON and SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthrough therapies against otherwise undruggable disease-causing targets, today announced upcoming presentations featuring preclinical data on its novel dual KRASG12C inhibitor FMC-376 and advances from the Frontier™ Platform. These data will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place April 14th-19th in Orlando, Florida.
Preclinical data unveiling FMC-376’s discovery and unique mode of action will be featured in an oral mini-symposium on Small Molecule Therapeutic Agents on April 16th, followed by a presentation on the Frontier Platform in an April 18th poster session.
“Decades after the human genome project, there remains a high unmet need for effective and durable breakthrough precision medicines targeting previously undruggable targets like KRAS,” said Chris Varma, Ph.D., Frontier’s co-founder, chairman, and CEO. “We are excited to share data showing how our novel dual inhibitor FMC-376 is designed to rapidly and directly shut down both active and inactive KRASG12C. These findings further validate the ability of the Frontier™ Platform to unlock the proteome for the discovery of treatments that can potentially create a better future for people with cancer and other serious conditions.”
Details on the presentations are as follows:
Presentation Information
| Title: | Discovery of FMC-376 a novel orally bioavailable inhibitor of activated KRASG12C |
| Abstract Number: | 1142 |
| Oral Session Title: | Small Molecule Therapeutic Agents |
| Session Date and Time: | Sunday, April 16, 2023, 3-5 p.m. ET |
| Title: | Combining chemoproteomics with machine learning identifies functionally active covalent fragments for hard-to-drug cancer drivers |
| Abstract Number: | 5333 |
| Poster Session Title: | High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery |
| Session Date and Time: | Tuesday, April 18, 2023, 1:30-5 p.m. ET |
About Frontier Medicines
Frontier Medicines is a precision medicine company that has pioneered a powerful drug discovery engine, the Frontier™ Platform, designed to generate medicines against disease-causing proteins previously considered undruggable. The company is deploying its technologies in chemoproteomics, covalent drug discovery, and machine learning to develop potentially groundbreaking medicines for genetically-defined patient populations, starting in cancer. Frontier is advancing a deep pipeline of wholly-owned precision medicines against the most important drivers of cancer. The company’s lead candidate, FMC-376, is a dual inhibitor of active and inactive KRASG12C. By completely blocking both forms of the KRAS mutation, FMC-376 has the potential to overcome the non-response and resistance seen with single-acting KRASG12C inhibitors. For more information on how Frontier is boldly advancing science to defeat disease, visit www.frontiermeds.com and follow us on LinkedIn and Twitter.
Investor and Media Relations Contact:
Victoria Fort
VP, Corporate Affairs
202.361.0445
victoria.fort@frontiermeds.com
